Posts tagged CEO at GOSH
ViroCell Biologics announces pivotal partnership with Great Ormond Street
ViroCell Biologics announces pivotal partnership with Great Ormond Street

Innovation-driven viral vector manufacturer, ViroCell Biologics, and Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH), have announced a new partnership that aims to dislodge the gene and cell therapy bottleneck.

Read More
In the NewsFlorence BuchananCDMO, GOSH, Zayed Centre for Research, clean rooms, cell and gene therapies, 1L to 200L batch size, viral vectors, lentivirus vector, AAV vectors, CGT, gene therapy, cell therapy, Pharmafile, UK CDMO, Matthew Shaw, CEO at GOSH, Great Ormond Street Hospital